Innovations that reach the patient: Early health technology assessment and improving the chances of coverage and implementation

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
24 Downloads (Pure)

Abstract

With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of health economic analyses in coverage decisions is likely to grow. One of the strategies for the biomedical research field-also in oncology research-to foster coverage and health system implementation, is to anticipate this new role and to involve health technology assessment techniques earlier in various stages of translational research. In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of Coverage with Evidence Development in The Netherlands Cancer Institute and give two case examples that are currently ongoing: (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer. We conclude with recommendations for institutional policy.

Original languageEnglish
Article number683
JournalEcancermedicalscience
Volume10
DOIs
Publication statusPublished - 28 Oct 2016

Fingerprint

Biomedical Technology Assessment
Translational Medical Research
Organizational Policy
Triple Negative Breast Neoplasms
Tumor-Infiltrating Lymphocytes
Health
Budgets
Netherlands
Biomedical Research
Melanoma
Neoplasms
Economics
Delivery of Health Care
Drug Therapy
Research
Therapeutics

Keywords

  • Coverage with evidence development
  • Health technology assessment
  • High-dose chemotherapy
  • Tumour infiltrating lymphocytes

Cite this

@article{47dbeea30e1241c9b9191004948ec94a,
title = "Innovations that reach the patient: Early health technology assessment and improving the chances of coverage and implementation",
abstract = "With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of health economic analyses in coverage decisions is likely to grow. One of the strategies for the biomedical research field-also in oncology research-to foster coverage and health system implementation, is to anticipate this new role and to involve health technology assessment techniques earlier in various stages of translational research. In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of Coverage with Evidence Development in The Netherlands Cancer Institute and give two case examples that are currently ongoing: (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer. We conclude with recommendations for institutional policy.",
keywords = "Coverage with evidence development, Health technology assessment, High-dose chemotherapy, Tumour infiltrating lymphocytes",
author = "{Van Harten}, {W. H.} and Ret{\`e}l, {V. P.}",
year = "2016",
month = "10",
day = "28",
doi = "10.3332/ecancer.2016.683",
language = "English",
volume = "10",
journal = "Ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - Innovations that reach the patient

T2 - Early health technology assessment and improving the chances of coverage and implementation

AU - Van Harten, W. H.

AU - Retèl, V. P.

PY - 2016/10/28

Y1 - 2016/10/28

N2 - With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of health economic analyses in coverage decisions is likely to grow. One of the strategies for the biomedical research field-also in oncology research-to foster coverage and health system implementation, is to anticipate this new role and to involve health technology assessment techniques earlier in various stages of translational research. In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of Coverage with Evidence Development in The Netherlands Cancer Institute and give two case examples that are currently ongoing: (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer. We conclude with recommendations for institutional policy.

AB - With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of health economic analyses in coverage decisions is likely to grow. One of the strategies for the biomedical research field-also in oncology research-to foster coverage and health system implementation, is to anticipate this new role and to involve health technology assessment techniques earlier in various stages of translational research. In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of Coverage with Evidence Development in The Netherlands Cancer Institute and give two case examples that are currently ongoing: (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer. We conclude with recommendations for institutional policy.

KW - Coverage with evidence development

KW - Health technology assessment

KW - High-dose chemotherapy

KW - Tumour infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84996508300&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2016.683

DO - 10.3332/ecancer.2016.683

M3 - Article

VL - 10

JO - Ecancermedicalscience

JF - Ecancermedicalscience

SN - 1754-6605

M1 - 683

ER -